The anandamide monounsaturated analogue oleoylethanolamide (OEA) acts as satiety signal released from enterocytes upon the ingestion of dietary fats to prolong the interval to the next meal. This effect, which requires intact vagal fibers and intestinal PPAR-alpha receptors, is coupled to the increase of c-fos and oxytocin mRNA expression in neurons of the paraventricular nucleus (PVN) and is prevented by the intracerebroventricular administration of a selective oxytocin antagonist, thus suggesting a necessary role of oxytocinergic neurotransmission in the pro-satiety effect of OEA. By brain microdialysis and immunohistochemistry, in this study we demonstrate that OEA treatment can stimulate oxytocin neurosecretion from the PVN and enhance ...
The neuropeptide oxytocin is produced in the paraventricular hypothalamic nucleus and the supraoptic...
Oleylethanolamide (OEA) is a natural analogue of the endogenous cannabinoid anandamide. Like anandam...
Binge eating disorder (BED) is the most frequent eating disorder, for which current pharmacotherapie...
The anandamide monounsaturated analogue oleoylethanolamide (OEA) acts as satiety signal released fro...
Oleoylethanolamide (OEA) is a biologically active lipid amide that is released by small-intestinal e...
Oleoylethanolamide (OEA) is a biologically active lipid amide that is released by small-intestinal e...
Oleoylethanolamide (OEA) is a gut-derived endogenous lipid that stimulates vagal fibers to induce sa...
The satiety-promoting action of oleoylethanolamide (OEA) has been associated to the indirect activat...
Oleoylethanolamide (OEA) is a biologically active lipid amide that is released by small-intestinal e...
Oleoylethanolamide (OEA) is a lipid amide produced by enterocytes upon the absorption of dietary fat...
Key factors driving eating behavior are hunger and satiety, which are controlled by a complex interp...
Binge eating disorder (BED) is the most frequent eating disorder, for which current pharmacothe...
Oleylethanolamide (OEA) is a natural analogue of the endogenous cannabinoid anandamide. Like anandam...
International audienceFatty acid ethanolamides are lipid compounds with biological activities. Among...
Chronic exposure to a diet rich in fats changes the gastrointestinal milieu and alters responses to ...
The neuropeptide oxytocin is produced in the paraventricular hypothalamic nucleus and the supraoptic...
Oleylethanolamide (OEA) is a natural analogue of the endogenous cannabinoid anandamide. Like anandam...
Binge eating disorder (BED) is the most frequent eating disorder, for which current pharmacotherapie...
The anandamide monounsaturated analogue oleoylethanolamide (OEA) acts as satiety signal released fro...
Oleoylethanolamide (OEA) is a biologically active lipid amide that is released by small-intestinal e...
Oleoylethanolamide (OEA) is a biologically active lipid amide that is released by small-intestinal e...
Oleoylethanolamide (OEA) is a gut-derived endogenous lipid that stimulates vagal fibers to induce sa...
The satiety-promoting action of oleoylethanolamide (OEA) has been associated to the indirect activat...
Oleoylethanolamide (OEA) is a biologically active lipid amide that is released by small-intestinal e...
Oleoylethanolamide (OEA) is a lipid amide produced by enterocytes upon the absorption of dietary fat...
Key factors driving eating behavior are hunger and satiety, which are controlled by a complex interp...
Binge eating disorder (BED) is the most frequent eating disorder, for which current pharmacothe...
Oleylethanolamide (OEA) is a natural analogue of the endogenous cannabinoid anandamide. Like anandam...
International audienceFatty acid ethanolamides are lipid compounds with biological activities. Among...
Chronic exposure to a diet rich in fats changes the gastrointestinal milieu and alters responses to ...
The neuropeptide oxytocin is produced in the paraventricular hypothalamic nucleus and the supraoptic...
Oleylethanolamide (OEA) is a natural analogue of the endogenous cannabinoid anandamide. Like anandam...
Binge eating disorder (BED) is the most frequent eating disorder, for which current pharmacotherapie...